1AE:F:F-Argen-X (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 545.6

Change

0.00 (0.00)%

Market Cap

USD 32.90B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
RGO:F Regeneron Pharmaceuticals Inc

-5.60 (-0.72%)

USD 84.33B
CSJ:F CSL Limited

+0.14 (+0.08%)

USD 83.49B
CSJA:F CSL LTD SPON.ADR 2

+1.50 (+1.73%)

USD 82.40B
UNC0:F UCB S.A. UNSP.ADR 1/2

-4.00 (-4.26%)

USD 34.23B
1AEA:F argenx SE

-5.00 (-0.91%)

USD 33.15B
DUL:F Alnylam Pharmaceuticals Inc

-2.50 (-0.96%)

USD 32.23B
22UA:F BioNTech SE

-2.80 (-2.72%)

USD 24.86B
49BA:F BeiGene Ltd

-6.00 (-3.06%)

USD 22.99B
49B:F BeiGene Ltd.

-0.50 (-3.40%)

USD 21.35B
0QF:F Moderna Inc

+0.65 (+1.62%)

USD 16.69B

ETFs Containing 1AE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.33% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.33% 81% B- 90% A-
Trailing 12 Months  
Capital Gain 20.07% 62% D 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.07% 62% D 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.76% 75% C 75% C
Dividend Return 13.76% 75% C 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.45% 92% A 74% C
Risk Adjusted Return 83.64% 99% N/A 91% A-
Market Capitalization 32.90B 99% N/A 94% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector